Accuracy and reliability of self-administered visual acuity tests: Systematic review of pragmatic trials.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 01 02 2023
accepted: 06 06 2023
medline: 26 6 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

Remote self-administered visual acuity (VA) tests have the potential to allow patients and non-specialists to assess vision without eye health professional input. Validation in pragmatic trials is necessary to demonstrate the accuracy and reliability of tests in relevant settings to justify deployment. Here, published pragmatic trials of these tests were synthesised to summarise the effectiveness of available options and appraise the quality of their supporting evidence. A systematic review was undertaken in accordance with a preregistered protocol (CRD42022385045). The Cochrane Library, Embase, MEDLINE, and Scopus were searched. Screening was conducted according to the following criteria: (1) English language; (2) primary research article; (3) visual acuity test conducted out of eye clinic; (4) no clinical administration of remote test; (5) accuracy or reliability of remote test analysed. There were no restrictions on trial participants. Quality assessment was conducted with QUADAS-2. Of 1227 identified reports, 10 studies were ultimately included. One study was at high risk of bias and two studies exhibited concerning features of bias; all studies were applicable. Three trials-of DigiVis, iSight Professional, and Peek Acuity-from two studies suggested that accuracy of the remote tests is comparable to clinical assessment. All other trials exhibited inferior accuracy, including conflicting results from a pooled study of iSight Professional and Peek Acuity. Two studies evaluated test-retest agreement-one trial provided evidence that DigiVis is as reliable as clinical assessment. The three most accurate tests required access to digital devices. Reporting was inconsistent and often incomplete, particularly with regards to describing methods and conducting statistical analysis. Remote self-administered VA tests appear promising, but further pragmatic trials are indicated to justify deployment in carefully defined contexts to facilitate patient or non-specialist led assessment. Deployment could augment teleophthalmology, non-specialist eye assessment, pre-consultation triage, and autonomous long-term monitoring of vision.

Sections du résumé

BACKGROUND
Remote self-administered visual acuity (VA) tests have the potential to allow patients and non-specialists to assess vision without eye health professional input. Validation in pragmatic trials is necessary to demonstrate the accuracy and reliability of tests in relevant settings to justify deployment. Here, published pragmatic trials of these tests were synthesised to summarise the effectiveness of available options and appraise the quality of their supporting evidence.
METHODS
A systematic review was undertaken in accordance with a preregistered protocol (CRD42022385045). The Cochrane Library, Embase, MEDLINE, and Scopus were searched. Screening was conducted according to the following criteria: (1) English language; (2) primary research article; (3) visual acuity test conducted out of eye clinic; (4) no clinical administration of remote test; (5) accuracy or reliability of remote test analysed. There were no restrictions on trial participants. Quality assessment was conducted with QUADAS-2.
RESULTS
Of 1227 identified reports, 10 studies were ultimately included. One study was at high risk of bias and two studies exhibited concerning features of bias; all studies were applicable. Three trials-of DigiVis, iSight Professional, and Peek Acuity-from two studies suggested that accuracy of the remote tests is comparable to clinical assessment. All other trials exhibited inferior accuracy, including conflicting results from a pooled study of iSight Professional and Peek Acuity. Two studies evaluated test-retest agreement-one trial provided evidence that DigiVis is as reliable as clinical assessment. The three most accurate tests required access to digital devices. Reporting was inconsistent and often incomplete, particularly with regards to describing methods and conducting statistical analysis.
CONCLUSIONS
Remote self-administered VA tests appear promising, but further pragmatic trials are indicated to justify deployment in carefully defined contexts to facilitate patient or non-specialist led assessment. Deployment could augment teleophthalmology, non-specialist eye assessment, pre-consultation triage, and autonomous long-term monitoring of vision.

Identifiants

pubmed: 37347757
doi: 10.1371/journal.pone.0281847
pii: PONE-D-23-02806
pmc: PMC10286971
doi:

Substances chimiques

polyetheretherketone 31694-16-3

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0281847

Informations de copyright

Copyright: © 2023 Thirunavukarasu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

We have read the journal’s policy and the authors of this manuscript have the following competing interests: AJT worked from July 2020-March 2021 as an unpaid research intern on clinical validation projects for a remote visual acuity test, DigiVis. This does not alter our adherence to PLOS ONE policies on sharing data and materials. None of the other authors have competing interests to declare.

Références

Clin Ophthalmol. 2021 Oct 04;15:4015-4027
pubmed: 34675470
Ophthalmic Physiol Opt. 2015 Nov;35(6):631-6
pubmed: 26497296
Eye (Lond). 2006 Jul;20(7):749-54
pubmed: 16327799
Ophthalmol Retina. 2021 Mar;5(3):224-233
pubmed: 32595096
Br Ir Orthopt J. 2021 Jan 21;17(1):13-19
pubmed: 34278213
Ophthalmol Sci. 2021 Mar 10;1(1):100007
pubmed: 36246005
J Telemed Telecare. 2019 Feb;25(2):106-122
pubmed: 29165005
J Fr Ophtalmol. 2021 Jun;44(6):873-881
pubmed: 34024655
Ophthalmol Ther. 2021 Dec;10(4):715-730
pubmed: 34169468
Eye (Lond). 2022 Oct;36(10):2057-2061
pubmed: 34462579
Front Hum Neurosci. 2021 Sep 14;15:733179
pubmed: 34594196
J Clin Nurs. 2015 Dec;24(23-24):3380-8
pubmed: 26335133
NPJ Digit Med. 2019 Nov 26;2:117
pubmed: 31799424
Ophthalmic Physiol Opt. 2011 Jul;31(4):330-8
pubmed: 21615445
Eye (Lond). 2021 Nov;35(11):3035-3040
pubmed: 33414531
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Digit Health. 2022 Oct 17;8:20552076221132105
pubmed: 36276185
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Cornea. 2022 Mar 1;41(3):353-358
pubmed: 34839329
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3278-81
pubmed: 12882770
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
Transl Vis Sci Technol. 2019 Aug 19;8(4):27
pubmed: 31440424
Invest Ophthalmol Vis Sci. 1993 Jan;34(1):120-9
pubmed: 8425819
Lancet Glob Health. 2018 Aug;6(8):e924-e932
pubmed: 30012273
Retina. 2013 Oct;33(9):1863-70
pubmed: 23609122
Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1175-80
pubmed: 26931323
Clin Ophthalmol. 2021 Jul 28;15:3205-3211
pubmed: 34349497
J R Soc Med. 2023 May;116(5):181-182
pubmed: 37199678
J Telemed Telecare. 2023 Feb;29(2):81-90
pubmed: 33222600
Asia Pac J Ophthalmol (Phila). 2021 Feb 9;10(4):350-354
pubmed: 33606386
Invest Ophthalmol Vis Sci. 2013 Aug 13;54(8):5497-505
pubmed: 23860761
Jpn J Ophthalmol. 2022 Mar;66(2):193-198
pubmed: 35044563
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
JMIR Form Res. 2023 Jan 25;7:e41045
pubmed: 36696171
JAMA Ophthalmol. 2015 Aug;133(8):930-7
pubmed: 26022921
BMJ Open Ophthalmol. 2021 Sep 30;6(1):e000801
pubmed: 34651083
JAMA Ophthalmol. 2022 Feb 01;140(2):153-160
pubmed: 34913967
Acta Ophthalmol Scand. 1999 Dec;77(6):673-6
pubmed: 10634561
JAMA Ophthalmol. 2022 May 1;140(5):465-471
pubmed: 35357405
JAMA Ophthalmol. 2022 Feb 1;140(2):161
pubmed: 34913961
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
Prog Retin Eye Res. 2021 May;82:100900
pubmed: 32898686

Auteurs

Arun James Thirunavukarasu (AJ)

School of Clinical Medicine, University of Cambridge, Camybridge, United Kingdom.
Corpus Christi College, University of Cambridge, Cambridge, United Kingdom.

Refaat Hassan (R)

School of Clinical Medicine, University of Cambridge, Camybridge, United Kingdom.
Sidney Sussex College, University of Cambridge, Cambridge, United Kingdom.

Aaron Limonard (A)

School of Clinical Medicine, University of Cambridge, Camybridge, United Kingdom.
St John's College, University of Cambridge, Cambridge, United Kingdom.

Shalom Vitreous Savant (SV)

School of Clinical Medicine, University of Cambridge, Camybridge, United Kingdom.
St John's College, University of Cambridge, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH